Close Menu

NEW YORK — Diazyme Laboratories said on Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for its Diazyme DZ-Lite SARS-CoV-2 IgG antibody test.

The test runs on the company's fully automated DZ-Lite 300 Plus chemiluminescence analyzer and is designed to detect immunoglobulin G antibodies against SARS-CoV-2 using the virus' S and N proteins.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.